Faes Farma Overview

  • Year Founded
  • 1933

Year Founded

  • Status
  • Public

  • Employees
  • 2,611

Employees

  • Stock Symbol
  • FAE

Stock Symbol

  • Investments
  • 11

  • Share Price
  • $5.51
  • (As of Tuesday Closing)

Faes Farma General Information

Description

Faes Farma SA purpose is manufacturing and selling all kinds of chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal plants, as well as acquiring, purchasing, disposing of, investing in, holding, using, managing, administering, marketing and leasing corporations, securities and real estate, patents, trademarks and registered brands and equity interests. It is mainly engaged in the manufacture and sale of pharmaceutical products, as well as in the manufacture and sale of animal nutrition and health products. Its segments are Pharmaceutical and healthcare specialities, Animal nutrition and health, and Other segments. It generates majority of revenue from Pharmaceutical and healthcare specialities. It operates mainly in domestic and international markets.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Avenida Autonomia, 10
  • 48940 Leioa
  • Spain
+34 901
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
MAD
Corporate Office
  • Avenida Autonomia, 10
  • 48940 Leioa
  • Spain
+34 901

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Faes Farma Stock Performance

As of 17-Nov-2026, Faes Farma’s stock price is $5.51. Its current market cap is $1.72B with 311M shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$5.51 $5.60 $4.93 - $6.41 $1.72B 311M 170K $0.32

Faes Farma Financials Summary

As of 30-Jun-2026, Faes Farma has a trailing 12-month revenue of $813M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,969,622 1,868,528 1,100,507 1,048,383
Revenue 813,297 688,607 534,175 488,198
EBITDA 158,852 133,136 137,029 131,530
Net Income 98,197 89,823 120,503 99,445
Total Assets 1,646,512 1,576,215 887,693 858,423
Total Debt 444,549 499,820 23,825 26,945
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Faes Farma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Faes Farma‘s full profile, request access.

Request a free trial

Faes Farma Patents

Faes Farma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026146131-A1 Mesalazine microparticles Pending 30-Dec-2024
WO-2026146128-A1 Vitamin d3 nanostructured lipid carriers Pending 30-Dec-2024
WO-2026104388-A1 Decongestant controlled release drug delivery system Pending 12-Nov-2024
WO-2026062171-A1 Pyridopyrimidine derivative as histamine receptor inhibitor Pending 20-Sep-2024
AU-2023221541-A1 Bilastine composition for once-daily parenteral administration Pending 17-Feb-2022 A61K31/454
To view Faes Farma’s complete patent history, request access »

Faes Farma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Faes Farma Investments & Acquisitions (11)

Faes Farma’s most recent deal was a Merger/Acquisition with SIFI for . The deal was made on 02-Sep-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
SIFI 02-Sep-2025 Merger/Acquisition Pharmaceuticals
Edol 04-Jun-2025 Merger/Acquisition Pharmaceuticals
NovoSci 23-Dec-2022 Merger/Acquisition Distributors (Healthcare)
Global Farma 08-Mar-2021 Merger/Acquisition Pharmaceuticals
BCN Medical 30-Oct-2019 Merger/Acquisition Distributors (Healthcare)
You’re viewing 5 of 11 investments and acquisitions. Get the full list »

Faes Farma ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

30.98 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Faes Farma’s complete esg history, request access »

Faes Farma Affiliates

Subsidiaries (4)

Name Industry Location Year Founded
Initial Technical Foods Lanciego, Spain 2010
Tecnologia & Vitaminas Tarragona, Spain 1997
Edol Carnaxide, Portugal 1952
SIFI Aci Sant'Antonio, Italy 1935

Faes Farma FAQs

  • When was Faes Farma founded?

    Faes Farma was founded in 1933.

  • Where is Faes Farma headquartered?

    Faes Farma is headquartered in Leioa, Spain.

  • What is the size of Faes Farma?

    Faes Farma has 2,611 total employees.

  • What industry is Faes Farma in?

    Faes Farma’s primary industry is Pharmaceuticals.

  • Is Faes Farma a private or public company?

    Faes Farma is a Public company.

  • What is Faes Farma’s stock symbol?

    The ticker symbol for Faes Farma is FAE.

  • What is the current stock price of Faes Farma?

    As of 17-Nov-2026 the stock price of Faes Farma is $5.51.

  • What is the current market cap of Faes Farma?

    The current market capitalization of Faes Farma is $1.72B.

  • What is Faes Farma’s current revenue?

    The trailing twelve month revenue for Faes Farma is $813M.

  • What is Faes Farma’s annual earnings per share (EPS)?

    Faes Farma’s EPS for 12 months was $0.32.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process